Coronavirus - Drug Discovery and Therapeutic Options

COVID-19 is basically a medium size RNA virus and the nucleic acid about 30 kb long, positive in sense, single stranded polyadenylated. The which found this largest known codes for large polyprotein. In addition, coronaviruses are capable of genetic recombination if 2 viruses infect same cell at time. SARS-CoV emerged first southern China rapidly spread around globe 2002–2003. November 2002, an unusual epidemic atypical pneumonia with high rate nosocomial transmission to health-care workers occurred Foshan, Guangdong, China. March 2003, novel CoV was confirmed be causative agent SARS, thus named SARS-CoV. Despite report number virus-based host-based treatment options potent vitro activities SARS MERS, only few likely fulfil their potential clinical setting foreseeable future. Most drugs have one or more major limitations that prevent them from proceeding beyond stage. First, many EC50/Cmax ratios clinically relevant dosages.